G-202-006: An Open-Label, Single-Arm, Phase II Study to Evaluate the Safety and Activity of G-202 in Patients With Clear Cell Renal Cell Carcinoma That Expresses PSMA
Phase of Trial: Phase II
Latest Information Update: 27 Feb 2017
At a glance
- Drugs Mipsagargin (Primary)
- Indications Renal cell carcinoma
- Focus Therapeutic Use
- Sponsors Inspyr Therapeutics
- 22 Feb 2017 Status changed from recruiting to completed.
- 06 Sep 2016 According to a Inspyr media release, first patient has been treated in this trial. The company expects top-line results second half 2017.
- 02 Jul 2016 Planned End Date changed from 1 Aug 2018 to 1 Oct 2018.